COMMUNIQUÉS West-GlobeNewswire

rYojbaba Announces Participation in the Guardian Girls Aikido Project in Los Angeles, CA
23/02/2026
FUKUOKA, Japan, Feb. 23, 2026 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) ("rYojbaba" or the "Company") , a Japanese consulting and health services company, collaborated with Guardian Girls USA and United [...]
Blue Genes Partners with RxSense to Deliver Actionable PGx at the Point of Adjudication
23/02/2026
The new partnership will enhance pharmacy benefit decision-making by embedding real-time genetic intelligence into adjudication workflows SCOTTSDALE, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Blue Genes today announced a [...]
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
23/02/2026
Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease HOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin [...]
Coherus Oncology to Participate in Upcoming Investor Conferences
23/02/2026
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible [...]
LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
23/02/2026
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) , a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December [...]
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
23/02/2026
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 GLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the [...]
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
23/02/2026
TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
23/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Nucleus Upgrades Preview, The First True Glimpse of Your Future Child
23/02/2026
Couples can now model 100 potential children across rare and common diseases, offering the most complete picture of inheritance yet. NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nucleus Genomics today introduced Preview [...]
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a [...]
ICU Medical to Participate in Upcoming Investor Conferences
23/02/2026
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the [...]
Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger
23/02/2026
DENVER, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wall Street opens to a convergence of science, scale, and strategic consolidation. From spider silk making mainstream headlines to multibillion-dollar oncology deals and [...]
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
23/02/2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” [...]
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
23/02/2026
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS ), a clinical- [...]
Bicara Therapeutics to Participate in Upcoming Investor Conferences
23/02/2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
23/02/2026
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making [...]
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
23/02/2026
HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
23/02/2026
U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast cancer Artios is launching a global randomized Phase 2 study to evaluate [...]
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a [...]

Pages